Kallikrein 5/KLK5 Protein, Mouse, Recombinant (His)

Description: The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. References: Thorpe JH, et al. Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome. Acta Crystallogr F Struct Biol Commun. 2019 May 1,75(Pt 5):385-39doi: 10.1107/S2053230X19003169. Epub 2019 Apr 26. PMID: 31045568, PMCID: PMC6497096.